DeepMed Research

MILLENNIUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.takedaoncology.com

Clinical Trials

PROTECT-TIMI 30 Trial

Phase 3

Completed

Conditions: Unstable Angina

First Posted Date: 2005-11-08

Last Posted Date: 2005-11-08

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 900

Registration Number: NCT00250471

A Study of MLN8054 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Breast Neoplasm
Colon Neoplasm
Pancreatic Neoplasm
Bladder Neoplasm

Interventions: Drug: MLN8054

First Posted Date: 2005-11-07

Last Posted Date: 2008-04-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 63

Registration Number: NCT00249301

Locations: 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Phase 1

Completed

Conditions: Tumors

First Posted Date: 2005-08-11

Last Posted Date: 2008-02-11

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Registration Number: NCT00129207

Locations: 🇺🇸
Medical Center, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Adenocarcinoma, Bronchiolo-Alveolar

First Posted Date: 2005-07-06

Last Posted Date: 2011-02-17

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Registration Number: NCT00117351

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-05-20

Last Posted Date: 2009-03-26

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Registration Number: NCT00111319

Locations: 🇺🇸
Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Phase 2

Completed

Conditions: B-Cell Lymphoma
Follicular Lymphoma
Marginal Lymphoma

First Posted Date: 2004-06-15

Last Posted Date: 2008-02-11

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 66

Registration Number: NCT00085696

Locations: 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 10 locations

Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

First Posted Date: 2004-04-02

Last Posted Date: 2009-03-27

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT00080405

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

Phase 1

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2003-10-13

Last Posted Date: 2007-07-13

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 46

Registration Number: NCT00070837

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Medical College of Cornell University/ New York Presbyterian Hospital, New York, New York, United States
🇺🇸
Duke University Medical Center, Box 3532, Durham, North Carolina, United States

and more 1 locations

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Phase 1

Terminated

Conditions: Advanced Non-Small Cell Lung Cancer
Other Solid Tumors

First Posted Date: 2003-07-11

Last Posted Date: 2005-06-24

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 46

Registration Number: NCT00064636

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2003-07-11

Last Posted Date: 2012-01-13

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 600

Registration Number: NCT00063726

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Texas Oncology at Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

and more 73 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy